[Interferon therapy for brain tumor patients (author's transl)]

Area of Science:

• Oncology
• Immunology
• Virology

Context:

• Recurrent and metastatic brain tumors pose significant treatment challenges.
• Standard therapies include surgical removal and radiotherapy.
• Evaluating novel therapeutic agents is crucial for improving patient outcomes.

Purpose:

• To investigate the efficacy and safety of human Interferon-alpha (Hu-IFN-alpha) in patients with recurrent and metastatic brain tumors.
• To assess the impact of different Hu-IFN-alpha dosages on tumor response and immune parameters.

Summary:

• Nine patients with recurrent/metastatic brain tumors, post-standard treatment, received intramuscular Hu-IFN-alpha in low or high doses.
• Tumor regression of approximately 50% was observed in two cases over 4 months via CT scans.
• Hu-IFN-alpha was ineffective against rapidly progressing tumors but improved general condition and immune markers (PPD, PHA, lymphocyte counts, NK activity).
• No adverse side effects were reported.

Impact:

• Hu-IFN-alpha demonstrates a potential therapeutic role in specific brain tumor recurrence scenarios.
• The study highlights the importance of patient selection, as efficacy may depend on tumor growth rate.
• Further research is warranted to optimize Hu-IFN-alpha treatment protocols for brain tumors.